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Abstract
Discovery of novel DNA gyrase B inhibitors remains an attractive field in the search for
new antibacterial drugs to overcome the known bacterial resistance mechanisms. In
the present study, we designed and synthesized novel ethylurea derivatives of 4,5,6,7-
tetrahydrobenzo[1,2-d]thiazole-2,6-diamine, 2-(2-aminothiazol-4-yl)acetic acid, and
benzo[1,2-d]thiazole-2,6-diamine and evaluated their Escherichia coli DNA gyrase
inhibition. The most potent DNA gyrase inhibitors in the prepared library of
compounds were benzo[1,2-d]thiazoles 32–34, 36, and 37 with IC50 values in the
lowmicromolar range. Themost promising inhibitors identifiedwere evaluated against
selected Gram-positive and Gram-negative bacterial strains. Compound 33 showed a
MICof 50 μMagainst an E. coli efflux pump-defective strain, which suggests that efflux
decreases the on-target concentrations of these compounds.
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1 | INTRODUCTION
Antibacterial drug resistance is a serious threat to human health, with
bacteria such as Enterococcus faecium, Staphylococcus aureus, Klebsiella
pneumoniae, Acinetobacter baumannii, and Enterobacter spp. (i.e., the
“ESKAPE” bacteria) becoming multidrug resistant against the presently
available antibiotics.[1] To successfully fight infectionswith these “badbugs”
in the future, there is the continuous need for development of novel
antibacterial agents thatarenot liable totheexistingresistancemechanisms.
DNA gyrase and topoisomerase IV are type IIA bacterial
topoisomerases that are involved in modulation of DNA topology
during DNA replication, transcription, and recombination. As these
enzymes are essential for cell viability and are conserved across all
bacteria but are not found in human cells, this makes them attractive
targets for antibacterial drug discovery.[2]
DNA gyrase and topoisomerase IV are heterotetrameric proteins,
withDNA gyrase composed of twoGyrA and twoGyrB subunits (A2B2),
and topoisomerase IV of two ParC and ParE subunits (C2E2). The GyrB
and ParE subunits have the ATPase activities which are necessary for
providing the energy for the supercoiling and decatenation reactions of
the catalytic GyrA and ParC subunits. The aminocoumarin antibiotic
novobiocin interacts with the ATP binding sites of GyrB and ParE, but it
was withdrawn from the market because of its toxicity and lack of
efficacy.[3] In recent years, several structural classes of GyrB and ParE
inhibitors have been discovered through high-throughput screening,
virtual screening, andde-novodesign, inboth industryandacademia.[3–5]
Structure-based optimization of hits has resulted in potent GyrB and/or
Abbreviations: EDC, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide; GyrA, DNA gyrase
subunit A; GyrB, DNA gyrase subunit B; HOBt, 1-hydroxybenzotriazole; NMM, N-
methylmorpholine; ParC, topoisomerase IV subunit A; ParE, topoisomerase IV subunit B;
RA, residual activity.
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ParE inhibitors that have antibacterial activities mainly against Gram-
positive bacteria, such as the cyclothialidine,[6] ethylurea,[7–14] pyrazo-
lopyridone,[15,16] and pyrrolamide[17–19] classes (Figure 1). Rare
examples of GyrB and ParE inhibitors with antibacterial activities
against Gram-negative bacteria include pyrrolopyrimidines,[20] pyrimi-
dinoindoles,[21] and some pyrrolamides[18] (Figure 1). However, despite
extensive efforts to develop new ATPase GyrB/ParE inhibitors, none
has progressed beyond phase 1 clinical trials.[3]
We have recently designed and optimized several structural
classes of pyrrolamide-based DNA gyrase and topoisomerase IV
inhibitors, which were based on the 4,5,6,7-tetrahydrobenzo[1,2-d]-
thiazole-2,6-diamine,[22,23] benzo[1,2-d]thiazole-2,6-diamine,[24] 4-
aminopiperidine,[25] and aniline[26,27] scaffolds. In all of them, the
4,5-dibromopyrrolamide moiety was shown to be an important
structural feature, as it is necessary to achieve potent Escherichia
coli DNA gyrase inhibition. The 5,7-diarylbenzo[1,2-d]thiazole ethyl-
ureas (Figure 1) have already been reported to be potent DNA gyrase
inhibitors and to have broad-spectrum Gram-positive antibacterial
activities.[13,14] We describe here the design and synthesis of novel
thiazole-based ethylureas, and the evaluation of their E. coli DNA
gyrase inhibition and antibacterial activities against selected Gram-
positive and Gram-negative bacteria.
2 | RESULTS AND DISCUSSION
2.1 | Design
The crystal structures of DNA gyrase in complexes with ethylurea-
based inhibitors[12] show that their Asp73 (E. coli numbering) side-
chain carboxylate forms two hydrogen bonds with the two NH groups
of the ethylureamoiety, while the nitrogen atom of the central scaffold
forms an additional hydrogen bond with a conserved water molecule
(Figure 2). With this hydrogen bonding motif, ethylurea-based DNA
gyrase inhibitors mimic the binding of the adenine ring of ATP, while
additional interactions are formedwith the amino acids of the lipophilic
floor of the ATP binding site and with the Arg76 and Arg136 side-
chains.[3,4]
Based on the described binding mode, we have designed novel
DNA gyrase B inhibitors bearing ethylurea moiety at position 2 of the
thiazole moiety of the 4,5,6,7-tetrahydrobenzo[1,2-d]thiazole-2,6-
diamine (Figure 2, 5–15), 2-(2-aminothiazol-4-yl)acetic acid (Figure 2,
23–26), and benzo[1,2-d]thiazole-2,6-diamine (Figure 2, 30–38)
central scaffolds. Additional substituents were introduced to interact
with Arg76 and/or Arg136 side chains to improve binding affinity of
the designed compounds. The design of all three of these series of
compounds was supported by molecular docking to the E. coli DNA
gyrase ATP binding site, which predicted the characteristic hydrogen
bonding network that is shown in Figure 2.
2.2 | Chemistry
The synthesis of the 4,5,6,7-tetrahydrobenzo[1,2-d]thiazole-2,6-
diamine derivatives5–15 is outlined in Scheme1. The enantiomerically
pure starting (S)-4,5,6,7-tetrahydrobenzo[1,2-d]thiazole-2,6-diamine
(1) was synthesized according to the previously reported proce-
dure.[22,28] In the first step, the 6-amino group was selectively
protected as a tert-butylcarbamate using di-tert-butyl dicarbonate
(Boc2O) in tetrahydrofuran, to obtain 2, and then the 2-amino group
was reacted with ethyl isocyanate in chloroform to yield ethylurea 3.
The Boc protecting group of 3was removed by acidolysis with HCl gas
generated in situ by the slow addition of acetyl chloride to methanol.
The hydrochloride of 4was obtained first, andwas converted to its free
FIGURE 1 Representative synthetic GyrB and/or ParE inhibitors
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base as this offered higher yields under weakly alkaline conditions of
the following amide-bond formation step than seen for the reaction
with the hydrochloride of 4. Acylation of 4 with methyl malonyl
chloride in 1,4-dioxane at room temperature yielded ester 5, which
was hydrolyzed to its acid derivative 6 under alkaline conditions, and
converted to hydrazide 7 by ester hydrazinolysis. Amides 8 and 10–14
were prepared by coupling of amine 4 with the corresponding
carboxylic acids, using EDC/HOBt coupling reagents. Benzoic acid
derivative 9 was prepared by alkaline hydrolysis of ester 8, while
acidolysis of the tert-butylcarbamate 14 resulted in amine 15.
The designed 2-(2-aminothiazol-4-yl)acetic acid derivatives
23–26 were prepared according to the synthetic procedures
presented in Scheme 2. Amine 16 was converted to tert-butylcarba-
mate 17 using Boc2O, to acetamide 18 using acetyl chloride, and to
ethylurea 19 using ethyl isocyanate. Compounds 17–19 were then
hydrolyzed under alkaline conditions, to their carboxylic acid counter-
parts 20–22. Carboxylic acid 22 was coupled in the following step to
methyl 3-aminobenzoate andmethyl 4-aminobenzoate using EDC and
HOBt, to obtain compounds 23 and 24. Their carboxylic acid
derivatives 25 and 26 were prepared by alkaline hydrolysis.
Benzo[1,2-d]thiazoles 30–38 were synthesized as summarized
in Scheme 3. In the first step, ethylurea 28 was prepared from amine
27 and ethyl isocyanate in toluene. Reduction of the nitro group of
28 by catalytic hydrogenation provided amine 29, which was then
used for the further synthesis. The 6-amino group of 29was acylated
with ethyl oxalyl chloride to provide ester 30, which was hydrolyzed
to acid 31 using 1M NaOH. The coupling of amine 29 with 2-(2-
aminothiazol-4-yl)acetic acids 20–22 (Scheme 2) yielded compounds
32–34. In addition, amine 35, which was obtained by Boc
deprotection of 33, was acylated with methyl malonyl chloride to
FIGURE 2 The hydrogen bonds of the thiazole-based ethylureas in the ATP binding site of DNA gyrase (E. coli numbering) and designed
novel thiazole-based ethylurea DNA gyrase B inhibitors
SCHEME 1 Synthesis of compounds 6–13. Reagents and conditions: a) Boc2O, THF, r.t., 18 h. b) Ethyl isocyanate, CHCl3, r.t., 18 h. c)
Acetyl chloride, MeOH, 0°C, 1 h, then r.t., 18 h. d) Methyl malonyl chloride, Et3N, 1,4-dioxane, r.t., 18 h. e) 6: 1M NaOH, MeOH/H2O, r.t.,
24 h. f) 7: Hydrazine hydrate, EtOH, 80°C, 18 h. g) Carboxylic acid, EDC, HOBt, NMM, DMF, r.t., 24 h
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give 36 and ethyl oxalyl chloride to give 37. Hydrolysis of 37 then
gave carboxylic acid 38.
2.3 | Biological evaluation
Compounds 4–15, 23–26, and 30–38 were tested for E. coli DNA
gyrase inhibition using an in vitro DNA gyrase supercoiling assay
(Tables 1–3). These data are presented as residual activities of the E.
coli DNA gyrase at 100 or 10 µM of the tested compounds, or as IC50
values for the more active compounds, where the residual activities
were <50% at 100 µM of the tested compounds. The selected final
compounds were then screened for their antibacterial activities at
50 µM against two Gram-positive and two Gram-negative bacteria
strains: S. aureus (ATCC 25923) and Enterococcus faecalis (ATCC
29212), and E. coli (ATCC 25922) and Pseudomonas aeruginosa (ATCC
27853), respectively. In addition, the compounds that showed IC50
values less than 10 μM against E. coli DNA gyrase were tested against
two E. colimutant strains: E. coli JD17464, an lpxC deletionmutantwith
a defective outer membrane due to impaired lipid A biosynthesis; and
E. coli JW5503, which has a defective efflux pump due to deletion of a
tolC gene. The data from these antibacterial activity evaluations are
presented in Tables 1, 3, and 4.
The in vitro E. coli DNA gyrase inhibitory activities of the 4,5,6,7-
tetrahydrobenzo[1,2-d]thiazoles 4–15 and 2-(2-aminothiazol-4-yl)-
SCHEME 2 Synthesis of compounds 17–26. Reagents and conditions: a) 17: Boc2O, 4-dimethylaminopyridine, CH2Cl2, r.t., 18 h. b) 18:
Acetyl chloride, Et3N, CH2Cl2, r.t., 4 h. c) 19: Ethyl isocyanate, CHCl3, 50°C, 18 h. d) 2M NaOH, MeOH/H2O, r.t., 18 h. e) Amine, EDC, HOBt,
NMM, DMF, r.t., 24 h
SCHEME 3 Synthesis of compounds 28–38. Reagents and conditions. a) Ethyl isocyanate, Et3N, toluene, reflux, 24 h. b) H2, Pd/C, EtOH/
DMF, r.t., 48 h. c) Ethyl oxalyl chloride, Et3N, 1,4-dioxane, r.t., 18 h. d) 1M NaOH, MeOH/H2O, r.t., 18 h. e) Carboxylic acid, EDC, HOBt,
NMM, DMF, r.t., 18 h. f) Acetyl chloride, MeOH, 0°C, 1 h, then r.t., 18 h. g) Methyl malonyl chloride, Et3N, 1,4-dioxane, r.t., 18 h
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acetic acid derivatives 23–26 are presented in Tables 1 and 2. The
results show that these compounds are poor E. coli DNA gyrase
inhibitors, since only compounds 11, 12, and 14 inhibited the enzyme
at high micromolar concentrations. In contrast, some of the benzo[1,2-
d]thiazoleureas 30–38 (Table 3) showed low micromolar E. coli DNA
gyrase inhibition (IC50 values between 3.9 and 8.3 μM). Comparison of
the partially saturated 4,5,6,7-tetrahydrobenzo[1,2-d]thiazole 14
(IC50 = 350 μM; Table 1) and unsaturated benzo[1,2-d]thiazole 33
(IC50 = 3.9 μM; Table 3) suggests the importance of the cation-π
interactions between theArg76 side-chain and the phenyl ring of these
inhibitors (Figure 3). When the ethylurea moiety interacts with Asp73
in the DNA gyrase ATP binding site, the fused tetrahydrobenzene ring
of compounds 5–15 is positioned under the Glu50-Arg76 salt bridge.
Thus the cation-π interactions between Arg76 and the inhibitors
cannot be formed, which results in less potent inhibitory activities. A
similar phenomenon was reported previously in a comparison of the
TABLE 1 Inhibition of E. coli DNA gyrase and antibacterial activity of 4,5,6,7-tetrahydrobenzo[1,2-d]thiazoles 4–15
E. coli DNA gyrase inhibition Growth inhibition at 50 µM (%)











4 100 n.t.b n.t. n.t. n.t.
5 100 n.t. n.t. n.t. n.t.
6 100 n.t. n.t. n.t. n.t.
7 100 n.t. n.t. n.t. n.t.
8 69 n.t. n.t. n.t. n.t.
9 99 n.t. n.t. n.t. n.t.
10 65 6 14 8 3
11 610 ± 20 n.t. n.t. n.t. n.t.
12 900 ± 50 n.t. n.t. n.t. n.t.
13 65 8 14 3 2
14 350 ± 30 4 20 7 8




1.5 µM 3.0 µM 0.05 µM 3.0 µM
aPercentage residual activity of the enzyme at 100 μM compound.
bn.t., not tested.
cData for ciprofloxacin bacterial growth inhibition given as MICs.
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inhibitory activities of 4,5,6,7-tetrahydrobenzo[1,2-d]thiazoles[23] and
benzo[1,2-d]thiazoles[24] with a pyrrolamide moiety at position 2. The
lack of this cation-π interaction is probably also the reason for the
inactivity of the 2-(2-aminothiazol-4-yl)acetic acid derivatives 23–26
(Table 2).
All of the tested compounds were only weakly active or were
inactive at 50 µM against Gram-negative E. coli and P. aeruginosa and
Gram-positive S. aureus and E. faecalis (Tables 1 and 3). One of the
possible reasons for these weak antibacterial activities against these
bacteria might be their low micromolar DNA gyrase inhibition. Some
previously reported ethylurea-based compounds were shown to
have nanomolar DNA gyrase inhibition and antibacterial activity
against Gram-positive bacteria.[7–14] However, these compounds
usually lack activity against Gram-negative bacteria, which is often a
consequence of the efflux of these inhibitors. Similarly, in the
present study, the improved MIC values against the E. coli mutant
strain JW5503 for inhibitor 33 (MIC = 50 µM) (Table 4) suggests that
these compounds are efflux pump substrates. Furthermore, as no
improvements in the MICs against E. coli JD17464 were seen (Table
4), the efflux of these compounds and not their insufficient
penetration through the cell wall appears to be the major reason
for the absence of their antibacterial activity.
3 | CONCLUSIONS
A focused library of novel 4,5,6,7-tetrahydrobenzo[1,2-d]thiazole-, 2-(2-
aminothiazol-4-yl)acetic acid-, and benzo[1,2-d]thiazole-based ethylurea
derivatives was designed and prepared as potential DNA gyrase B
inhibitors.Themoleculardockingstudies showedhydrogenbondnetwork
formed with Asp73, structural water molecule and Arg136 in the ATP-
binding site of E. coli DNA gyrase. The results of the in vitro E. coli DNA
gyrase supercoiling assay showed that the most potent of these
compounds were benzo[1,2-d]thiazoles 32–34, 36, and 37 with IC50
values in the lowmicromolar range,while4,5,6,7-tetrahydrobenzo[1,2-d]-
thiazole and 2-(2-aminothiazol-4-yl)acetic acid derivatives were only
weakly active or inactive. Evaluation of the antibacterial activities showed
weak inhibitionofbacterial growthat50μMagainstS. aureus,E. faecalis,E.
coli, and P. aeruginosa. In both Gram-positive and Gram-negative bacteria
this could be the result of onlymicromolar enzyme inhibition and/or poor
penetration through the bacterial cell wall. In addition, the in vitro assays
on the E. coli efflux-pump-deficient strain (JW5503) indicated that these
compounds are efflux pump substrates in E. coli, which will result in
reduced cytoplasmic concentrations and hence poor antibacterial activity
against Gram-negative strains. Nevertheless, these structure–activity
relationshipsprovideabasis for furtheroptimizationof this structural class
of DNA gyrase inhibitors.
4 | EXPERIMENTAL
4.1 | Chemistry
4.1.1 | General procedures
Chemicals were obtained from Acros Organics (Geel, Belgium), Sigma–
Aldrich (St. Louis, MO, USA), and TCI Europe N.V. (Zwijndrecht,
Belgium) and used without further purification. Analytical TLC was
performed on silica gel Merck 60 F254 plates (0.25mm), using
visualization with UV light and spray reagents. Column chromatogra-
phywas carried out on silica gel 60 (particle size 240–400mesh). HPLC
analyses were performed on Agilent Technologies 1100 instrument
with G1365B UV-VIS detector, G1316A thermostat and G1313A
autosampler using Agilent Eclipse Plus C18 column (5 μm,
4.6 × 150mm) using Method A: mobile phase: 0.1% trifluoroacetic
acid in water (A) and acetonitrile (B); gradient: 2 min 95% A, 90% A to
10% A in 12min, 10% A to 5% A in 1min, then 5min 5% A; flow rate
1.0mL/min; injection volume: 10 µL. All tested compounds were
≥95% pure by HPLC. Melting points were determined on a Reichert
hot stage microscope and are uncorrected. 1H and 13C NMR spectra
were recorded at 400 and 100MHz, respectively, on a Bruker
AVANCE III 400 spectrometer (Bruker Corporation, Billerica, MA,
USA) in DMSO-d6 or CDCl3 solutions, with TMS as the internal
standard. Mass spectra were obtained using a VG Analytical Autospec
Qmass spectrometer (Fisons, VG Analytical, Manchester, UK). Optical
rotations were measured on a PerkinElmer 241 MC polarimeter. The
reported values for specific rotation are average values of five
successive measurements using an integration time of 5 s.
The InChI codes of the investigated compounds together with
some biological activity data are provided as Supporting Information.
4.1.2 | Synthetic procedures
tert-Butyl (S)-(2-amino-4,5,6,7-tetrahydrobenzo[1,2-d]thiazol-6-
yl)carbamate (2)
A solution of (S)-4,5,6,7-tetrahydrobenzo[1,2-d]thiazole-2,6-diamine
(1) (3.002 g, 17.8mmol) in tetrahydrofuran (THF) (100mL) was cooled
to 0°C on an ice bath. Then a solution of di-tert-butyl dicarbonate
TABLE 2 Inhibition of E. coliDNAgyrase by 2-(2-aminothiazol-4-yl)-
acetic acids 23–26
Compound R






These compounds were not tested for growth inhibition of S. aureus ATCC
25923, E. faecalisATCC25212, E. coliATCC25922, and P. aeruginosaATCC
27853.
aPercentage residual activity of the enzyme at 100 µM compound.
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(Boc2O) (4.068 g, 18.7 mmol) in THF (30 mL) was added dropwise
over 20 min. The reaction mixture was stirred at room temperature
overnight. The solvent was removed under reduced pressure and the
crude product dissolved in ethyl acetate (100 mL). Organic phase
was successively washed with saturated aqueous NaHCO3 solution
(100mL) and brine (100mL), dried over Na2SO4, filtered and the
solvent removed under reduced pressure. Product was used without
further purification. Yield: 4.79 g (100%); white solid; mp 140–
142°C; [α]D −40.3 (c 0.26, MeOH);
1H NMR (400MHz, DMSO-d6): δ
1.38 (s, 9H, C(CH3)3), 1.54–1.65 (m, 1H, HA-7), 1.80–1.86 (m, 1H,
HB-7), 2.31–2.47 (m, 3H, HA-4, H-5), 2.68 (dd, 1H,
J1 = 14.8 Hz, J2 = 5.5 Hz, HB-4), 3.57–3.69 (m, 1H, CHNH), 6.64 (s,
2H, NH2), 6.94 (d, 1H, J = 7.9 Hz, NH) ppm;
13C NMR (100MHz,




A solution of 2 (4.460 g, 16.6 mmol) in chloroform (100mL) was cooled
to 0°C on an ice bath under an argon atmosphere. Then ethyl
isocyanate (1.44mL, 18.2 mmol) was added dropwise over 20min. The
reaction mixture was stirred at room temperature overnight. Reaction
mixture was transferred to the separating funnel and successively
washed with saturated aqueous NaHCO3 solution (2 × 25mL) and
TABLE 3 Inhibition of E. coli DNA gyrase and antibacterial activity of benzo[1,2-d]thiazoles 30–38
E. coli DNA gyrase inhibition Growth inhibition at 50 µM (%)











30 82 4 6 0 16
31 79 0 7 0 0
32 7.0 ± 0.5 15 27 10 17
33 3.9 ± 0.1 64 51 15 35
34 5.6 ± 0.2 12 30 5 20
35 91 n.t.b n.t. n.t. n.t.
36 6.9 ± 0.2 25 16 1 1
37 8.3 ± 0.1 0 19 0 14




1.5 µM 3.0 µM 0.050 µM 3.0 µM
aResidual activity of the enzyme at 10 μM of compound.
bn.t., not tested.
cData for ciprofloxacin bacterial growth inhibition given as MICs.
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brine (100mL), dried over Na2SO4, filtered and the solvent removed
under reduced pressure. Crude product was purified by column
chromatography using dichloromethane/methanol (30:1) as eluent.
Yield: 2.29 g (40.7%); white solid; mp 183–185°C; [α]D −15.6 (c 0.22,
MeOH); 1H NMR (400MHz, DMSO-d6): δ 1.05 (t, 3H, J = 7.2 Hz,
CH2CH3), 1.40 (s, 9H, 3 × CH3), 1.61–1.71 (m, 1H, HA-7), 1.86–1.94 (m,
1H, HB-7), 2.38–2.47 (m, 1H, HA-5), 2.55–2.71 (m, 2H, HB-5, HA-4),
2.81 (dd, 1H, J1 = 15.7 Hz, J2 = 5.0 Hz, HB-4), 3.09–3.16 (m, 2H,
CH2CH3), 3.58–3.76 (m, 1H, CHNH), 6.50 (t, 1H, J = 5.0 Hz,
NHCH2CH3), 6.99 (d, 1H, J = 7.9 Hz, NHCH), 10.11 (s, 1H, NHCO)
ppm; 13C NMR (100MHz, DMSO-d6): δ 15.2, 24.8, 28.2 (3C), 28.5,
28.9, 34.1, 46.4, 77.6, 117.4, 144.8, 153.6, 155.0, 157.6 ppm; HRMS
(ESI+) m/z for C15H24N4O3S ([M+H]




Methanol (30mL) was cooled on an ice bath and then acetyl chloride
(4.80mL, 67.4mmol) was added dropwise. The mixture was stirred at
0°C for 30min and then solution of 3 (2.292 g, 6.74mmol) in methanol
(20mL) was added. Reaction mixture was stirred at 0°C for 1 h and
then at room temperature overnight. The solvent was evaporated
under reduced pressure, crude product dissolved in a small volume of
water and then 1M NaOH was added to reach pH∼ 12. Off-white
precipitate (1.615 g, 99.8%) was filtered off and dried. mp 121–123°C;
[α]D −34.5 (c 0.24, MeOH);
1H NMR (400MHz, DMSO-d6): δ 1.05 (t,
3H, J = 7.2 Hz, CH2CH3), 1.48–1.59 (m, 1H, HA-7), 1.82–1.89 (m, 1H,
HB-7), 2.25–2.32 (m, 1H, HA-5), 2.44–2.60 (m, 2H, HA-4, HB-5, signal
partially overlapped with DMSO-d5), 2.77 (dd, 1H, J1 = 15.6 Hz,
J2 = 4.8 Hz, HB-4), 3.01–3.07 (m, 1H, CHNH), 3.10–3.16 (m, 2H,
CH2CH3), 6.58 (s, 1H, NHCH2CH3) ppm; signals for NH2 and NHCO
are not seen in the spectrum; 13C NMR (100MHz, DMSO-d6): δ 15.7,
25.1, 32.2, 32.5, 34.5, 47.9, 118.3, 143.3, 154.3, 158.0 ppm; HRMS
(ESI+) m/z for C10H16N4OS ([M+H]




To a solution of 4 (0.159 g, 0.66mmol) and Et3N (0.138mL, 0.99mmol)
in 1,4-dioxane (30mL), methyl 3-chloro-3-oxopropanoate (0.092mL,
0.86mmol) was added dropwise under an argon atmosphere. Reaction
mixture was stirred at room temperature for 18 h. Solvent was
removed under reduced pressure and to the crude product ethyl
acetate (20 mL) was added. The precipitate was filtered off, washed
with ethyl acetate (5 mL), dried and then purified by flash column
chromatography using dichloromethane/methanol (40:1) as eluent.
Yield: 0.130 g (57.7%); off-white solid; mp 198–200°C; [α]D −10.1 (c
0.21, MeOH); 1H NMR (400MHz, DMSO-d6): δ 1.05 (t, 3H, J = 7.2 Hz,
CH2CH3), 1.71–1.80 (m, 1H, HA-7), 1.84–1.92 (m, 1H, HB-7), 2.42–
2.46 (m, 1H, HA-4), 2.56–2.63 (m, 2H, HA-5, HB-4), 2.87 (dd, 1H,
J1 = 16.0 Hz, J2 = 5.5 Hz, HB-5), 3.09–3.16 (m, 2H, CH2CH3), 3.25 (s,
2H, COCH2CO), 3.62 (s, 3H, COOCH3), 3.99–4.06 (m, 1H, CHNH),
6.76 (br s, 1H, NHCH2CH3), 8.18 (d, 1H, J = 7.6 Hz, CONHCH), 10.14
(br s, 1H, NHCO) ppm; HRMS (ESI-) m/z for C14H19N4O4S ([M–H]
−):
calcd. 339.1127, found 339.1121; HPLC: method A, tr 9.07min (100%
at 254 nm).
FIGURE 3 The docking binding mode of inhibitor 34 (in yellow)
in the ATP binding site of E. coli DNA gyrase B (in gray, PDB code:
4DUH[29]). The ligand and the neighboring protein side-chains are
shown as stick models, colored according to the chemical atom type
(blue, N; red, O; orange, S; green, Cl). Water molecule is presented
as a red sphere. Hydrogen bonds are indicated by black dotted lines
TABLE 4 Inhibition of E. coliDNA gyrase and antibacterial activities of compounds 32–34, 36, and 37 against wild-type E. coli and twomutant E.
coli strains
Growth inhibition
E. coli ATCC 25922 E. coli JW5503 E. coli JD17464
Compound E. coli DNA gyrase IC50 (µM) (%)
a MIC (µM) (%)a (%)a
32 7.0 ± 0.5 10 0 2
33 3.9 ± 0.1 15 50 37
34 5.6 ± 0.2 5 4 15
36 6.9 ± 0.2 1 0 1
37 8.3 ± 0.1 0 0 6
Ciprofloxacin (MIC)b 0.050 µM 0.015 µM 0.12 µM
aPercentage growth inhibition at 50 μM;
bData for ciprofloxacin bacterial growth inhibition given as MICs.
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(S)-3-((2-(3-Ethylureido)-4,5,6,7-tetrahydrobenzo[1,2-d]thiazol-
6-yl)amino)-3-oxopropanoic acid (6)
To a solution of 5 (0.037 g, 0.11 mmol) in methanol (10 mL), 1 M
NaOH (0.44 mL, 0.44 mmol) was added and the reaction mixture
stirred at room temperature for 3 h. Methanol was evaporated
under reduced pressure and reaction mixture extracted with ethyl
acetate (10 mL). Water phase was acidified with 1M HCl to pH ∼ 2,
precipitate was filtered off and purified by flash column chroma-
tography using dichloromethane/methanol/acetic acid (5:1:0.1) as
eluent. Yield: 0.021 g (59.2%); off-white solid; mp 130–132°C; [α]D
−12.6 (c 0.23, MeOH); 1H NMR (400MHz, DMSO-d6): δ 1.05 (t, 3H,
J = 7.2 Hz, CH2CH3), 1.70–1.80 (m, 1H, HA-7), 1.84–1.90 (m, 1H,
HB-7), 2.41–2.45 (m, 1H, HA-4), 2.56–2.68 (m, 2H, HA-5, HB-4),
2.87 (dd, 1H, J1 = 15.9 Hz, J2 = 4.9 Hz, HB-5), 3.09–3.16 (m, 2H,
CH2CH3), 3.22 (s, 2H, COCH2CO), 3.99–4.12 (m, 1H, CHNH), 6.54
(t, 1H, J = 5.4 Hz, NHCH2CH3), 8.20 (d, 1H, J = 7.5 Hz, CONHCH),
10.17 (br s, 1H, NHCO) ppm; signal for COOH not seen in the
spectrum; HRMS (ESI−) m/z for C13H17N4O4S ([M–H]
−): calcd.




To a solution of 5 (0.080 g, 0.24mmol) in ethanol (4 mL), hydrazine
monohydrate (0.143mL, 2.40mmol) was added and the reaction
mixture stirred at 80°C overnight. Ethanol was evaporated under
reduced pressure and the residue purified by flash column chroma-
tography using dichloromethane/methanol (9:1) as eluent. Yield:
0.075 g (93.8%); gray solid; mp 241–243°C; [α]D −16.3 (c 0.20,
MeOH); 1H NMR (400MHz, DMSO-d6): δ 1.05 (t, 3H, J = 7.1 Hz,
CH2CH3), 1.70–1.80 (m, 1H, HA-7), 1.83–1.90 (m, 1H, HB-7), 2.40–
2.45 (m, 1H, HA-4), 2.58–2.63 (m, 2H, HA-5, HB-4), 2.87 (dd, 1H,
J1 = 15.4 Hz, J2 = 4.5 Hz, HB-5), 2.98 (s, 2H, COCH2CO), 3.09–3.16 (m,
2H, CH2CH3), 3.97–4.06 (m, 1H, CHNH), 4.24 (br s, 2H, NHNH2), 6.52
(t, 1H, J = 4.7 Hz, NHCH2CH3), 8.12 (d, 1H, J = 7.6 Hz, CONHCH), 9.08
(s, 1H, NHNH2), 10.17 (br s, 1H, NHCO) ppm; HRMS (ESI
−) m/z for
C13H19N6O3S ([M–H]
−): calcd. 339.1239, found 339.1234; HPLC:
method A, tr 7.99min (100% at 254 nm).
4.1.3 | General procedure A
A solution of carboxylic acid (1 mmol) in N,N-dimethylformamide
(10mL) was cooled to 0°C and then EDC (1.2 mmol) and HOBt
(1.3 mmol) were added. pH was adjusted to 8 with N-methylmorpho-
line and the reaction mixture stirred for 20 min at 0°C. Then amine
(1 mmol) was added and reaction mixture stirred overnight at room
temperature. The solvent was evaporated in vacuo and the oily
residue dissolved in ethyl acetate (30 mL) and washed successively
with 10% citric acid (2 × 30mL), saturated aqueous NaHCO3 solution
(2 × 30mL), and brine (30 mL). The organic phase was dried over




Compound was prepared from 4 (0.195 g, 0.81mmol) and 3-
(methoxycarbonyl)benzoic acid (0.146 g, 0.81mmol) according to
the general procedure A. Crude product was purified by column
chromatography using dichloromethane/methanol (20:1) as eluent.
Yield: 0.138 g (42.2%); yellowish solid; mp 174–176°C; [α]D −12.6 (c
0.30, DMF); 1H NMR (400MHz, DMSO-d6): δ 1.06 (t, 3H, J = 7.1 Hz,
CH2CH3), 1.86–1.91 (m, 1H, HA-7), 2.00–2.03 (m, 1H, HB-7), 2.63–
2.70 (m, 3H, HA-5, H-4), 2.95 (dd, 1H, J1 = 15.3 Hz, J2 = 5.2 Hz, HB-5),
3.12–3.18 (m, 2H, CH2CH3), 3.90 (s, 3H, COOCH3), 4.20–4.29 (m, 1H,
CHNH), 6.52 (t, 1H, J = 5.6 Hz, NHCH2CH3), 7.64 (t, 1H, J = 7.8 Hz, Ar-
H-5), 8.10–8.15 (m, 2H, Ar-H-4, Ar-H-6), 8.46 (t, 1H, J = 1.6 Hz, Ar-H-
2), 8.73 (d, 1H, J = 7.7 Hz, CONHCH), 10.14 (s, 1H, NHCO) ppm;
13C NMR (100MHz, DMSO-d6): δ 15.2, 24.9, 28.2, 28.6, 34.1, 46.2,
52.3, 117.4, 128.0, 128.9, 129.7, 131.6, 132.1, 135.1, 142.9, 153.7,
157.5, 164.9, 165.8 ppm; HRMS (ESI−)m/z for C19H21N4O4S ([M–H]
−):
calcd. 401.1284, found 401.1286; HPLC: method A, tr 10.89min
(98.7% at 254 nm).
(S)-3-((2-(3-Ethylureido)-4,5,6,7-tetrahydrobenzo[1,2-d]thiazol-
6-yl)carbamoyl)benzoic acid (9)
To a solution of 8 (0.138 g, 0.34mmol) in methanol (5 mL), 1M NaOH
(1.02mL, 1.02mmol) was added and the reaction mixture stirred at
room temperature overnight. Methanol was evaporated under
reduced pressure and reaction mixture extracted with ethyl acetate
(10mL).Water phase was acidified with 1MHCl to pH∼ 2. Precipitate
was filtered off and dried. Water phase was extracted with ethyl
acetate (3 × 20mL), combined organic phases were washedwith brine,
dried over Na2SO4, filtered and the solvent evaporated under reduced
pressure. Yield: 0.132 g (99.1%); pink solid; mp 220–222°C; [α]D −16.3
(c 0.29, MeOH); 1H NMR (400MHz, DMSO-d6): δ 1.07 (t, 3H,
J = 7.2 Hz, CH2CH3), 1.85–1.93 (m, 1H, HA-7), 1.99–2.05 (m, 1H, HB-
7), 2.61–2.73 (m, 3H, HA-5, H-4), 2.97 (dd, 1H, J1 = 15.5 Hz, J2 = 4.9 Hz,
HB-5), 3.14–3.18 (m, 2H, CH2CH3), 4.22–4.30 (m, 1H, CHNH), 7.14 (br
s, 1H, NHCH2CH3), 7.61 (t, 1H, J = 7.7 Hz, Ar-H-5), 8.08–8.12 (m, 2H,
Ar-H-4, Ar-H-6), 8.44 (s, 1H, Ar-H-2), 8.74 (d, 1H, J = 7.5 Hz,
CONHCH), 10.99 (br s, 1H, NHCO) ppm; signal for COOH not seen
in the spectrum; 13C NMR (100MHz, DMSO-d6): δ 14.9, 22.7, 27.5,
27.9, 34.3, 45.4, 118.3, 128.1, 128.7, 130.8, 131.7, 131.8, 134.8,
137.0, 152.7, 159.9, 165.2, 166.9 ppm; HRMS (ESI−) m/z for
C18H19N4O4S ([M–H]
−): calcd. 387.1127, found 387.1118; HPLC:
method A, tr 9.95min (98.4% at 254 nm).
(S)-N-(2-(3-Ethylureido)-4,5,6,7-tetrahydrobenzo[1,2-d]thiazol-
6-yl)-4-methylthiazole-5-carboxamide (10)
Compound was prepared from 4 (0.084 g, 0.35mmol) and 4-
methylthiazole-5-carboxylic acid (0.050 g, 0.35mmol) according to
the general procedure A. Crude product was purified by column
chromatography using dichloromethane/methanol (20:1) as eluent.
Yield: 0.092 g (72.0%); yellow solid; mp 198–200°C; [α]D −8.0 (c 0.26,
MeOH); 1H NMR (400MHz, DMSO-d6): δ 1.05 (t, 3H, J = 7.1 Hz,
CH2CH3), 1.80–1.90 (m, 1H, HA-7), 1.96–2.03 (m, 1H, HB-7), 2.56 (s,
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3H, CH3), 2.58–2.69 (m, 3H, HA-5, H-4), 2.92 (dd, 1H, J1 = 15.3 Hz,
J2 = 4.5 Hz, HB-5), 3.09–3.16 (m, 2H, CH2CH3), 4.11–4.21 (m, 1H,
CHNH), 6.73 (s, 1H, NHCH2CH3), 8.37 (d, 1H, J = 7.7 Hz, CONHCH),
9.05 (s, 1H, Ar-H), 10.25 (s, 1H, NHCO) ppm; 13C NMR (100MHz,
DMSO-d6): δ 15.2, 16.7, 24.8, 28.0, 28.4, 34.0, 46.2, 117.1, 126.3,
142.8, 153.4, 153.9, 154.2, 157.5, 160.9 ppm; HRMS (ESI+) m/z for
C15H19N5O2S2 ([M+H]
+): calcd. 366.1058, found 366.1058; HPLC:
method A, tr 9.56min (100% at 254 nm).
(S)-N-(2-(3-Ethylureido)-4,5,6,7-tetrahydrobenzo[1,2-d]thiazol-
6-yl)-5-methylisoxazole-4-carboxamide (11)
Compound was prepared from 4 (0.082 g, 0.34mmol) and 4-
methylisoxazole-4-carboxylic acid (0.050 g, 0.34mmol) according to
the general procedure A. Crude product was purified by column
chromatography using dichloromethane/methanol (40:1) as eluent.
Yield: 0.030 g (21.8%); yellow solid; mp 160–162°C; [α]D −10.0 (c 0.19,
DMF); 1H NMR (400MHz, DMSO-d6): δ 1.05 (t, 3H, J = 7.2 Hz,
CH2CH3), 1.65–1.72 (m, 1H, HA-7), 1.76–1.93 (m, 1H, HB-7), 1.99 (s,
3H, CH3), 2.54–2.64 (m, 3H, HA-5, H-4), 2.92 (dd, 1H, J1 = 16.1 Hz,
J2 = 4.8 Hz, HB-5), 3.09–3.16 (m, 2H, CH2CH3), 3.52–3.61 (m, 1H,
CHNH), 6.77 (s, 1H, NHCH2CH3), 6.98 (d, 1H, J = 6.0 Hz, CONHCH),
8.41 (s, 1H, Ar-H), 10.27 (s, 1H, NHCO) ppm; HRMS (ESI+) m/z for
C15H19N5O3S ([M+H]
+): calcd. 350.1287, found 350.1286; HPLC:
method A, tr 11.09min (95.0% at 254 nm).
(S)-N-(2-(3-Ethylureido)-4,5,6,7-tetrahydrobenzo[1,2-d]thiazol-
6-yl)-1H-imidazole-4-carboxamide (12)
Compound was prepared from 4 (0.108 g, 0.45mmol) and 1H-
imidazole-4-carboxylic acid (0.050 g, 0.45mmol) according to the
general procedure A. Crude product was purified by column
chromatography using dichloromethane/methanol (9:1) as eluent.
Yield: 0.005 g (3.4%); yellow solid; mp 180–182°C; [α]D −18.3 (c 0.20,
MeOH); 1H NMR (400MHz, MeOD-d4): δ 1.19 (t, 3H, J = 7.2 Hz,
CH2CH3), 1.97–2.04 (m, 1H, HA-7), 2.12–2.19 (m, 1H, HB-7), 2.68–
2.82 (m, 3H, HA-5, H-4), 3.08 (dd, 1H, J1 = 15.5 Hz, J2 = 5.6 Hz, HB-5),
3.23–3.31 (m, 2H, CH2CH3), 4.37–4.43 (m, 1H, CHNH), 7.70 (d, 1H,
J = 1.0 Hz, Ar-H), 7.74 (d, 1H, J = 1.0 Hz, Ar-H) ppm; signals for NH
groups are not seen in the spectrum; HRMS (ESI+) m/z for
C14H18N6O2S ([M+H]
+): calcd. 335.1290, found 335.1297; HPLC:
method A, tr 8.48min (100% at 254 nm).
(S)-N-(2-(3-Ethylureido)-4,5,6,7-tetrahydrobenzo[1,2-d]thiazol-
6-yl)isonicotinamide (13)
Compound was prepared from 4 (0.82 g, 0.34mmol) and pyridine-4-
carboxylic acid (0.042 g, 0.34mmol) according to the general
procedure A. Crude product was purified by column chromatography
using dichloromethane/methanol (20:1) as eluent. Yield: 0.013 g
(11.0%); white solid; mp 125–127°C; [α]D −6.3 (c 0.18, DMF);
1H NMR (400MHz, DMSO-d6): δ 1.06 (t, 3H, J = 7.2 Hz, CH2CH3),
1.82–1.92 (m, 1H, HA-7), 1.98–2.05 (m, 1H, HB-7), 2.61–2.69 (m, 3H,
HA-5, H-4), 2.95 (dd, 1H, J1 = 15.3 Hz, J2 = 4.8 Hz, HB-5), 3.10–3.17 (m,
2H, CH2CH3), 4.17–4.27 (m, 1H, CHNH), 6.51 (t, 1H, J = 5.5 Hz,
NHCH2CH3), 7.77 (dd, 2H, J1 = 4.4 Hz, J2= 1.7 Hz, Ar-H), 8.73 (dd, 2H,
J1 = 4.4 Hz, J2 = 1.7 Hz, Ar-H), 8.77 (d, 1H, J = 7.7 Hz, CHNH), 10.14 (s,
1H, NHCO) ppm; 13C NMR (100MHz, DMSO-d6): δ 15.2, 24.5, 28.1,
28.5, 34.1, 46.2, 117.2, 121.4 (2C), 141.5, 150.1 (2C), 153.7, 157.7,
157.9, 164.4 ppm; HRMS (ESI+)m/z for C16H19N5O2S ([M+H]
+): calcd.





Compound was prepared from 4 (0.067 g, 0.28mmol) and 2-(2-((tert-
butoxycarbonyl)amino)thiazol-4-yl)acetic acid (0.071 g, 0.28mmol)
according to the general procedure A. Yield: 0.098 g (74.2%); yellow
solid; mp 140–142°C; [α]D −6.0 (c 0.27, MeOH);
1H NMR (400MHz,
DMSO-d6): δ 1.05 (t, 3H, J = 7.2 Hz, CH2CH3), 1.48 (s, 9H, C(CH3)3),
1.68–1.79 (m, 1H, HA-7), 1.84–1.94 (m, 1H, HB-7), 2.39–2.47 (m, 1H,
HA-4), 2.54–2.70 (m, 2H, HB-4, HA-5), 2.86 (dd, 1H, J1 = 16.1 Hz,
J2 = 5.5 Hz, HB-5), 3.08–3.17 (m, 2H, CH2CH3), 3.42 (s, 2H, Ar-CH2),
3.95–4.02 (m, 1H, CHNH), 6.51 (t, 1H, J = 5.6 Hz, NHCH2CH3), 6.81 (s,
1H, Ar-H), 8.11 (d, 1H, J = 7.5 Hz, CHNH), 10.12 (s, 1H, NHCO), 11.39
(s, 1H, NHCO) ppm; 13C NMR (100MHz, CDCl3): δ 15.3, 28.2 (3C),
29.0, 35.0, 39.1, 44.8, 55.4, 66.9, 77.2, 109.8, 115.6, 116.1, 117.5,
143.2, 152.4, 154.6, 159.8, 161.2 ppm; HRMS (ESI+) m/z for
C20H28N6O4S2 ([M+H]
+): calcd. 481.1692, found 481.1685; HPLC:
method A, tr 11.28min (100% at 254 nm).
(S)-2-(2-Aminothiazol-4-yl)-N-(2-(3-ethylureido)-4,5,6,7-
tetrahydrobenzo[1,2-d]thiazol-6-yl)acetamide (15)
Methanol (5 mL) was cooled on an ice bath and then acetyl chloride
(0.108mL, 1.52mmol) was added dropwise. Themixture was stirred at
0°C for 30min and then solution of 14 (0.073 g, 0.15mmol) in
methanol (5 mL) was added. Reactionmixture was stirred at 0°C for 1 h
and then at room temperature overnight. Then solventwas evaporated
under reduced pressure and crude product purified by column
chromatography using dichloromethane/methanol (9:1) as eluent.
Yield: 0.032 g (55.2%); yellow solid; mp 120–122°C; [α]D −5.7 (c 0.22,
MeOH); 1H NMR (400MHz, DMSO-d6): δ 1.03 (t, 3H, J = 7.2 Hz,
CH2CH3), 1.67–1.78 (m, 1H, HA-7), 1.84–1.93 (m, 1H, HB-7), 2.53–
2.60 (m, 3H, H-4, HA-5), 2.84 (dd, 1H, J1 = 15.2 Hz, J2 = 5.3 Hz, HB-5),
3.06–3.12 (m, 2H, CH2CH3), 3.26 (s, 2H, Ar-CH2), 3.92–4.00 (m, 1H,
CHNH), 6.21 (s, 1H, NHCH2CH3), 6.89 (s, 2H, NH2), 7.99 (s, 1H, Ar-H),
8.14 (d, 1H, J = 7.7 Hz, CHNH), 11.08 (br s, 1H, NHCO) ppm; HRMS
(ESI+) m/z for C15H20N6O2S2 ([M+H]
+): calcd. 381.1167, found
381.1162; HPLC: method A, tr 8.60min (96.5% at 254 nm).
Ethyl 2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetate (17)
To a solution of 16 (1.077 g, 5.78mmol) and catalytic amount of 4-
dimethylaminopyridine in dichloromethane (50mL) a solution of di-
tert-butyl dicarbonate (Boc2O) (1.640 g, 7.52mmol) in dichloro-
methane (20mL) was added dropwise over 20min. The reaction
mixture was stirred at room temperature overnight. The solvent was
removed under reduced pressure and the crude product dissolved in
ethyl acetate (100mL). Organic phase was successively washed with
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saturated aqueous NaHCO3 solution (100mL) and brine (100mL),
dried over Na2SO4, filtered, and the solvent removed under reduced
pressure. Product was used in the next step without further
purification. Yield: 1.655 g (100%); yellow solid; mp 128–130°C;
1HNMR (400MHz, DMSO-d6): δ 1.18 (t, 3H, J = 7.1 Hz, CH2CH3), 1.48
(s, 9H, C(CH3)3), 3.64 (d, 2H, J = 0.7 Hz, CH2), 4.07 (q, 2H, J = 7.1 Hz,
OCH2CH3), 6.92 (s, 1H, Ar-H), 11.44 (br s, 1H, NHCO) ppm; MS (ESI
−)
m/z for C12H17N2O4S ([M–H]
−): 285 (100).
Ethyl 2-(2-acetamidothiazol-4-yl)acetate (18)
A solution of 16 (1.066 g, 5.73mmol) and triethylamine (1.040mL,
7.46mmol) in dichloromethane (50mL) was cooled to 0°C on an ice
bath under an argon atmosphere. Then acetyl chloride (0.450mL,
6.33mmol) was added dropwise. The reaction mixture was stirred at
room temperature for 4 h. Organic phase was successively washed
with 10% citric acid (2 × 20mL), saturated aqueous NaHCO3 solution
(2 × 20mL) and brine (20mL), dried over Na2SO4, filtered and the
solvent removed under reduced pressure. Crude product was
crystallized from a mixture of ethyl acetate/hexane (1:2). Yield:
0.591 g (45.3%); yellow solid; mp 112–114°C; 1H NMR (400MHz,
DMSO-d6): δ 1.18 (t, 3H, J = 7.1 Hz, CH2CH3), 2.12 (s, 3H, COCH3),
3.68 (s, 2H, CH2), 4.08 (q, 2H, J = 7.1 Hz, OCH2CH3), 6.95 (s, 1H, Ar-H),
12.14 (br s, 1H, NHCO) ppm; 13C NMR (100MHz, DMSO-d6): δ 14.6,




A solution of 16 (4.214 g, 22.7mmol) in chloroform (100mL) was
cooled to 0°C on an ice bath under an argon atmosphere. Then ethyl
isocyanate (2.87mL, 36.2 mmol) was added dropwise over 20min. The
reaction mixture was stirred at 50°C overnight. Reaction mixture was
transferred to the separating funnel and successively washed with
saturated aqueous NaHCO3 solution (2 × 25mL) and brine (100mL),
dried over Na2SO4, filtered and the solvent removed under reduced
pressure. Crude product was purified by column chromatography
using ethyl acetate/n-hexane (1:6) as eluent. Yield: 2.665 g (45.8%);
white solid; mp 152–154°C; 1H NMR (400MHz, DMSO-d6): δ 1.06 (t,
3H, J = 7.2 Hz, NHCH2CH3), 1.18 (t, 3H, J = 7.1 Hz, OCH2CH3), 3.09–
3.17 (m, 2H, NHCH2CH3), 3.60 (s, 2H, CH2), 4.08 (q, 2H, J = 7.1 Hz,
OCH2CH3), 6.45 (br s, 1H, NHCH2CH3), 6.76 (s, 1H, Ar-H), 10.44 (br s,
1H, NHCO) ppm; 13C NMR (100MHz, DMSO-d6): δ 14.5, 15.7, 34.6,




To a solution of 17 (1.655 g, 5.79mmol) in methanol (20mL), 2M
NaOH (11.6 mL, 23.2mmol) was added and the reaction mixture
stirred at room temperature overnight. Reaction mixture was then
stirred at 50°C for additional 2 h. Methanol was evaporated under
reduced pressure and reaction mixture extracted with ethyl acetate
(2 × 20mL). Water phase was acidified with concentrated HCl to
pH∼ 2. Precipitate was filtered off and dried. Yield: 0.822 g (55.1%);
yellow solid; mp 160–162°C; 1H NMR (400MHz, DMSO-d6): δ 1.48 (s,
9H, C(CH3)3), 3.55 (s, 2H, CH2), 6.89 (s, 1H, Ar-H), 11.42 (br s, 1H,
NHCO), 12.35 (s, 1H, COOH) ppm; 13C NMR (100MHz, DMSO-d6): δ
28.4 (3C), 37.3, 81.5, 110.0, 144.9, 159.7, 159.8, 172.1 ppm;MS (ESI−)
m/z for C10H13N2O4S ([M–H]
−): 257 (100).
2-(2-Acetamidothiazol-4-yl)acetic acid (21)
To a solution of 19 (0.591 g, 2.59mmol) in methanol (20mL), 2M
NaOH (5.2mL, 10.4mmol) was added and the reaction mixture stirred
at room temperature overnight. Reaction mixture was then stirred at
50°C for additional 2 h. Methanol was evaporated under reduced
pressure and reactionmixture extractedwith ethyl acetate (2 × 20mL).
Water phase was acidified with concentrated HCl to pH∼ 2. Water
phase was extracted with ethyl acetate (3 × 50mL), combined organic
phases washed with brine (100mL), dried over Na2SO4, filtered and
the solvent removed under reduced pressure. Yield: 0.138 g (26.6%);
yellowish solid; mp 211–213°C; 1HNMR (400MHz, DMSO-d6): δ 2.12
(s, 3H, COCH3), 3.58 (s, 2H, CH2), 6.92 (s, 1H, Ar-H), 12.12 (br s, 1H,
NHCO), 12.36 (br s, 1H, COOH) ppm; 13C NMR (100MHz, DMSO-d6):




To a solution of 19 (2.645 g, 10.3 mmol) in ethanol (20mL), 2MNaOH
(20.6mL, 41.2 mmol) was added and the reaction mixture stirred at
room temperature overnight. Ethanol was evaporated under reduced
pressure and reactionmixture extractedwith ethyl acetate (2 × 25mL).
Water phase was acidified with concentrated HCl to pH∼ 2.
Precipitate was filtered off and dried. Yield: 2.308 g (97.9%); white
solid; mp 173–175°C; 1H NMR (400MHz, DMSO-d6): δ 1.06 (t, 3H,
J = 7.2 Hz, NHCH2CH3), 3.10–3.17 (m, 2H, NHCH2CH3), 3.51 (s, 2H,
CH2), 6.45 (t, 1H, J = 4.8 Hz, NHCH2CH3), 6.74 (s, 1H, Ar-H), 10.41 (br
s, 1H, NHCO), 12.29 (s, 1H, COOH) ppm; 13C NMR (100MHz, DMSO-
d6): δ15.2, 34.0, 36.6, 108.4, 142.9, 153.8, 159.6, 171.5 ppm.MS (ESI
+)




Compound was prepared from 22 (0.076 g, 0.33mmol) and methyl
3-aminobenzoate (0.050 g, 0.33 mmol) according to the general
procedure A. Crude product was purified by column chromatography
using dichloromethane/methanol (40:1) as eluent. Yield: 0.030 g
(25.0%); yellow solid; mp 140–142°C; 1H NMR (400MHz, DMSO-
d6): δ 1.05 (t, 3H, J = 7.2 Hz, NHCH2CH3), 3.10–3.17 (m, 2H,
NHCH2CH3), 3.62 (s, 2H, CH2), 3.85 (s, 3H, COOCH3), 6.44 (t, 1H,
J = 5.2 Hz, NHCH2CH3), 6.78 (s, 1H, thiazole-H), 7.46 (t, 1H,
J = 8.0 Hz, Ar-H-5), 7.64 (ddd, 1H, J1 = 8.0 Hz, J2 = 2.0 Hz,
J3 = 1.1 Hz, Ar-H-4/6), 7.85 (ddd, 1H, J1 = 8.0 Hz, J2 = 2.0 Hz,
J3 = 1.1 Hz, Ar-H-4/6), 8.29 (t, 1H, J = 2.0 Hz, Ar-H-2), 10.35 (s,
1H, NHCO), 10.40 (s, 1H, NHCO) ppm; 13C NMR (100MHz, DMSO-
d6): δ 15.2, 34.1, 52.2, 108.2, 119.5, 123.5, 123.8, 129.2, 130.1,
139.5, 144.4, 153.7, 159.7, 159.8, 166.1, 168.3 ppm; HRMS (ESI−)
m/z for C16H17N4O4S ([M–H]
−): calcd. 361.0971, found 361.0975;
HPLC: method A, tr 11.16min (100% at 254 nm).
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Methyl 4-(2-(2-(3-ethylureido)thiazol-4-yl)acetamido)benzoate (24)
Compound was prepared from 22 (0.200 g, 0.87mmol) and methyl 4-
aminobenzoate (0.132 g, 0.87mmol) according to the general proce-
dure A. Crude product was purified by column chromatography using
dichloromethane/methanol (20:1) as eluent. Yield: 0.066 g (20.9%);
orange solid; mp 122–124°C; 1HNMR (400MHz, DMSO-d6): δ 1.04 (t,
3H, J = 7.2 Hz, NHCH2CH3), 3.10–3.16 (m, 2H, NHCH2CH3), 3.65 (s,
2H, CH2), 3.83 (s, 3H, COOCH3), 6.43 (t, 1H, J = 5.3 Hz, NHCH2CH3),
6.78 (s, 1H, thiazole-H), 7.75 (d, 2H, J = 8.8 Hz, Ar-H), 7.92 (d, 2H,
J = 8.8 Hz, Ar-H), 10.42 (s, 1H, NHCO), 10.48 (s, 1H, NHCO) ppm;
13C NMR (100MHz, DMSO-d6): δ 15.2, 34.1, 51.9, 108.3, 118.4 (2C),
123.8, 130.3 (2C), 143.6, 144.2, 153.7, 159.7 (2C), 165.8, 168.6 ppm;
HRMS (ESI−) m/z for C16H17N4O4S ([M–H]
−): calcd. 361.0971, found
361.0977; HPLC: method A, tr 11.19min (100% at 254 nm).
3-(2-(2-(3-Ethylureido)thiazol-4-yl)acetamido)benzoic acid (25)
To a solution of 23 (0.015 g, 0.041mmol) in methanol (5 mL), 2M
NaOH (0.062mL, 0.12mmol) was added and the reaction mixture
stirred at room temperature overnight. Methanol was evaporated
under reduced pressure and water phase acidified with concentrated
HCl to pH∼ 2. Precipitate was filtered off and dried. Yield: 0.012 g
(83.2%); brown solid; mp 154–156°C; 1H NMR (400MHz, DMSO-d6):
δ 1.04 (t, 3H, J = 7.2 Hz, NHCH2CH3), 3.10–3.16 (m, 2H, NHCH2CH3),
3.63 (s, 2H, CH2), 6.56 (t, 1H, J = 5.1 Hz, NHCH2CH3), 6.78 (s, 1H,
thiazole-H), 7.43 (t, 1H, J = 7.9 Hz, Ar-H-5), 7.62 (d, 1H, J = 7.9 Hz, Ar-
H-4/6), 7.84 (d, 1H, J = 7.9 Hz, Ar-H-4/6), 8.25 (s, 1H, Ar-H-2), 10.35 (s,
1H, NHCO), 10,48 (s, 1H, NHCO), 12.97 (br s, 1H, COOH) ppm;
13C NMR (100MHz, DMSO-d6): δ 15.2, 34.1, 108.2, 119.7, 123.1,
124.0, 129.0, 131.2, 137.9, 139.4, 144.0, 153.6, 159.8, 167.1,
168.2 ppm; HRMS (ESI−) m/z for C15H15N4O4S ([M–H]
−): calcd.
347.0814, found 347.0818; HPLC: method A, tr 9.99min (100% at
254 nm).
4-(2-(2-(3-Ethylureido)thiazol-4-yl)acetamido)benzoic acid (26)
To a solution of 24 (0.039 g, 0.11mmol) in methanol (5 mL), 2MNaOH
(0.16mL, 0.32mmol) was added and the reaction mixture stirred at
room temperature overnight. Methanol was evaporated under
reduced pressure and water phase acidified with concentrated HCl
to pH∼ 2. Precipitate was filtered off and dried. Yield: 0.028 g (74.7%);
yellow solid; mp 248–250°C; 1H NMR (400MHz, DMSO-d6): δ 1.05 (t,
3H, J = 7.2 Hz, NHCH2CH3), 3.11–3.17 (m, 2H, NHCH2CH3), 3.68 (s,
2H, CH2), 6.68 (t, 1H, J = 5.8 Hz, NHCH2CH3), 6.81 (s, 1H, thiazole-H),
7.73 (d, 2H, J = 8.9 Hz, Ar-H), 7.89 (d, 2H, J = 8.9 Hz, Ar-H), 10.51 (s,
1H, NHCO), 10.61 (br s, 1H, NHCO) ppm; signal for COOH not seen in
the spectrum; 13C NMR (100MHz, DMSO-d6): δ 15.1, 34.2, 108.8,
118.3 (2C), 125.1, 130.4 (2C), 142.2, 143.2, 153.4, 160.3, 166.9,
168.2 ppm; HRMS (ESI−) m/z for C15H15N4O4S ([M–H]
−): calcd.
347.0814, found 347.0804; HPLC: method A, tr 9.91min (100% at
254 nm).
1-Ethyl-3-(6-nitrobenzo[1,2-d]thiazol-2-yl)urea (28)
To a suspension of 27 (4.88 g, 25.0 mmol) in toluene (100mL), triethyl
amine (3.49mL, 25.0mmol) and ethyl isocyanate (1.98mL, 25.0mmol)
were added and the reaction mixture stirred under reflux overnight.
The reaction mixture was then cooled on an ice bath, precipitate
filtered off and dried to obtain 28 as a yellow solid. Yield: 5.75 g
(86.0%); 1H NMR (400MHz, DMSO-d6): δ 1.10 (t, 3H, J = 7.2 Hz,
NHCH2CH3), 3.17–3.24 (m, 2H, NHCH2CH3), 6.80 (s, 1H,
NHCH2CH3), 7.74 (d, 1H, J = 8.9 Hz, Ar-H-4), 8.21 (dd, 1H,
J1 = 8.9 Hz, J2 = 2.5 Hz, Ar-H-5), 8.94 (d, 1H, J = 2.5 Hz, Ar-H-7),
11.20 (s, 1H, NHCO) ppm; 13C NMR (100MHz, DMSO-d6): δ 15.0,
34.4, 118.5, 119.4, 121.6, 132.2, 142.2, 153.4, 154.3 165.3 ppm.
1-(6-Aminobenzo[1,2-d]thiazol-2-yl)-3-ethylurea (29)
Compound 28 (1.512 g, 5.68mmol) was dissolved in a mixture of
ethanol (100mL) and N,N-dimethylformamide (30mL), Pd-C (150mg)
was added and the reaction mixture was stirred under hydrogen
atmosphere for 48 h. The catalyst was filtered off and the solvent
removed under reduced pressure. Crude product was purified by
column chromatography using dichloromethane/methanol (20:1) as
eluent. Yield: 0.411 g (30.6%); brown solid; mp 198–200°C; 1H NMR
(400MHz, DMSO-d6): δ 1.07 (t, 3H, J = 7.2 Hz, NHCH2CH3), 3.13–
3.20 (m, 2H, NHCH2CH3), 5.03 (s, 2H, NH2), 6.63 (dd, 1H, J1 = 8.5 Hz,
J2 = 2.2 Hz, Ar-H-5), 6.68 (t, 1H, J = 5.8 Hz, NHCH2CH3), 6.94 (d, 1H,
J = 2.2 Hz, Ar-H-7), 7.29 (d, 1H, J = 8.5 Hz, Ar-H-4), 10.28 (s, 1H,




To a solution of 29 (0.100 g, 0.42mmol) and Et3N (0.147mL, 1.1 mmol)
in 1,4-dioxane (20mL), ethyl 2-chloro-2-oxoacetate (0.057mL,
0.51mmol) was added dropwise under an argon atmosphere. Reaction
mixture was stirred at room temperature for 18 h. The precipitate was
filtered off, solvent was removed under reduced pressure and the
crude product purified by flash column chromatography using
dichloromethane/methanol (20:1) as eluent. Yield: 0.015 g (10.5%);
yellow solid; mp 253–255°C; 1H NMR (400MHz, DMSO-d6): δ 1.10 (t,
3H, J = 7.2 Hz, NHCH2CH3), 1.33 (t, 3H, J = 7.1 Hz, COOCH2CH3),
3.15–3.22 (m, 2H, NHCH2CH3), 4.32 (q, 2H, J = 7.1 Hz, COOCH2CH3),
6.71 (t, 1H, J = 6.0 Hz, NHCH2CH3), 7.59 (d, 1H, J = 8.7 Hz, Ar-H-4),
7.67 (dd, 1H, J1 = 8.7 Hz, J2 = 1.9 Hz, Ar-H-5), 8.21 (d, 1H, J = 1.9 Hz,
Ar-H-7), 10.68 (s, 1H, NHCO), 10.88 (s, 1H, NHCO) ppm; 13C NMR
(100MHz, DMSO-d6): δ 13.8, 15.1, 34.2, 62.3, 113.0, 119.3, 119.5,
131.7, 132.5, 145.9, 155.3, 159.6, 160.7, 168.4 ppm; HRMS (ESI−)m/z
for C14H15N4O4S ([M–H]
−): calcd. 335.0814, found 335.0810; HPLC:
method A, tr 11.06min (95.9% at 254 nm).
2-((2-(3-Ethylureido)benzo[1,2-d]thiazol-6-yl)amino)-2-
oxoacetic acid (31)
To a solution of 30 (0.010 g, 0.030mmol) in methanol (3 mL), 1M
NaOH (0.060mL, 0.060mmol) was added and the reaction mixture
stirred at room temperature overnight. Then the acidic ion exchange
resin Amberlite® IR120 H was added for neutralization (pH∼ 6). After
stirring of mixture for 10min, the resin was filtered off, washed with
methanol and the solvent removed in vacuo. Yield: 0.008 g (86.9%);
yellow solid; mp >300°C; 1H NMR (400MHz, DMSO-d6): δ 1.09 (t, 3H,
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J = 7.2 Hz, NHCH2CH3), 3.15–3.22 (m, 2H, NHCH2CH3), 6.73 (t, 1H,
J = 5.6 Hz, NHCH2CH3), 7.57 (d, 1H, J = 8.7 Hz, Ar-H-4), 7.69 (dd, 1H,
J1 = 8.7 Hz, J2 = 2.0 Hz, Ar-H-5), 8.31 (d, 1H, J = 2.0 Hz, Ar-H-7), 10.67
(s, 1H, NHCO), 10.78 (s, 1H, NHCO) ppm, signal for COOH not seen in
the spectrum; 13C NMR (100MHz, DMSO-d6): δ 15.1, 34.2, 112.6,
116.5, 119.1, 119.4, 125.7, 131.6, 132.8, 159.5, 162.2, 163.3 ppm;
HRMS (ESI−) m/z for C12H11N4O4S ([M–H]
−): calcd. 307.0501, found
307.0499; HPLC: method A, tr 9.36min (100% at 254 nm).
N-(2-(3-Ethylureido)benzo[1,2-d]thiazol-6-yl)-2-(2-(3-
ethylureido)thiazol-4-yl)acetamide (32)
Compound was prepared from 22 (0.097 g, 0.42mmol) and 29
(0.100 g, 0.42mmol) according to the general procedure A. Crude
product was crystallized from a mixture of dichloromethane and
methanol (20:1). Yield: 0.066 g (34.7%); brown solid; mp 250–252°C;
1H NMR (400MHz, DMSO-d6): δ 1.05 (t, 3H, J = 7.2 Hz, NHCH2CH3),
1.09 (t, 3H, J = 7.2 Hz, NHCH2CH3), 3.10–3.21 (m, 4H,
2 × NHCH2CH3), 3.62 (s, 2H, CH2), 6.45 (t, 1H, J = 5.4 Hz, NHCH2CH3),
6.71 (t, 1H, J = 4.5 Hz, NHCH2CH3), 6.77 (s, 1H, thiazole-H), 7.46 (dd,
1H, J1 = 8.7 Hz, J2 = 1.9 Hz, Ar-H-5), 7.54 (d, 1H, J = 8.7 Hz, Ar-H-4),
8.21 (d, 1H, J = 1.9 Hz, Ar-H-7), 10.20 (s, 1H, NHCO), 10.41 (s, 1H,
NHCO), 10.61 (s, 1H, NHCO) ppm; 13C NMR (100MHz, DMSO-d6): δ
15.1, 15.2, 34.1, 34.2, 40.1, 108.0, 111.3, 118.0, 119.5, 131.7, 134.4,
144.6, 145.0, 145.1, 153.7, 158.9, 162.3, 167.8 ppm; HRMS (ESI−)m/z
for C18H20N7O3S2 ([M–H]
−): calcd. 446.1096, found 446.1076; HPLC:
method A, tr 10.44min (97.2% at 254 nm).
tert-Butyl (4-(2-((2-(3-ethylureido)benzo[1,2-d]thiazol-6-yl)-
amino)-2-oxoethyl)thiazol-2-yl)carbamate (33)
Compound was prepared from 20 (0.108 g, 0.42 mmol) and 29
(0.100 g, 0.42 mmol) according to the general procedure A. Crude
product was crystallized from a mixture of dichloromethane and
methanol (20:1). Yield: 0.085 g (42.1%); yellow solid; mp 172–174°C;
1H NMR (400MHz, DMSO-d6): δ 1.09 (t, 3H, J = 7.2 Hz,
NHCH2CH3), 1.48 (s, 9H, C(CH3)3), 3.15–3.22 (m, 2H, NHCH2CH3),
3.66 (s, 2H, CH2), 6.73 (t, 1H, J = 4.7 Hz, NHCH2CH3), 6.92 (s, 1H,
thiazole-H), 7.46 (dd, 1H, J1 = 8.7 Hz, J2 = 2.0 Hz, Ar-H-5), 7.54 (d,
1H, J = 8.7 Hz, Ar-H-4), 8.20 (d, 1H, J = 2.0 Hz, Ar-H-7), 10.21 (s, 1H,
NHCO), 10.63 (s, 1H, NHCO), 11.44 (s, 1H, NHCO) ppm; 13C NMR
(100MHz, DMSO-d6): δ 15.1, 27.9 (3C), 34.2, 40.4, 80.9, 109.3,
111.3, 118.0, 119.5, 131.7, 134.4, 145.1, 145.2, 152.8, 153.7, 158.9,
159.3, 167.7 ppm; HRMS (ESI−) m/z for C20H23N6O4S2 ([M–H]
−):
calcd. 475.1222, found 475.1213. HPLC: method A, tr 10.54 min
(96.1% at 254 nm).
2-(2-Acetamidothiazol-4-yl)-N-(2-(3-ethylureido)benzo[1,2-d]-
thiazol-6-yl)acetamide (34)
Compound was prepared from 21 (0.077 g, 0.39mmol) and 29
(0.091 g, 0.39mmol) according to the general procedure A. Crude
product was crystallized from a mixture of dichloromethane and
methanol (20:1). Yield: 0.043 g (26.7%); yellow solid; mp 263–265°C;
1H NMR (400MHz, DMSO-d6): δ 1.09 (t, 3H, J = 7.2 Hz, NHCH2CH3),
2.11 (s, 3H, COCH3), 3.15–3.21 (m, 2H, NHCH2CH3), 3.70 (s, 2H, CH2),
6.70 (t, 1H, J = 5.0 Hz, NHCH2CH3), 6.95 (s, 1H, thiazole-H), 7.46 (dd,
1H, J1 = 8.7 Hz, J2 = 2.0 Hz, Ar-H-5), 7.54 (d, 1H, J = 8.7 Hz, Ar-H-4),
8.20 (d, 1H, J = 2.0 Hz, Ar-H-7), 10.23 (s, 1H, NHCO), 10.63 (s, 1H,
NHCO), 12.11 (s, 1H, NHCO) ppm; 13C NMR (100MHz, DMSO-d6): δ
15.1, 22.4, 34.2, 40.1, 109.7, 111.3, 118.0, 119.5, 131.8, 134.4, 145.0,
145.2, 153.6, 157.6, 158.9, 167.7, 168.3 ppm; HRMS (ESI−) m/z for
C17H17N6O3S2 ([M–H]
−): calcd. 417.0804, found 417.0797; HPLC:
method A, tr 10.40min (100% at 254 nm).
2-(2-Aminothiazol-4-yl)-N-(2-(3-ethylureido)benzo[1,2-d]-
thiazol-6-yl)acetamide (35)
Methanol (10 mL) was cooled on an ice bath and then acetyl chloride
(0.860mL, 12.1 mmol) was added dropwise. Themixture was stirred at
0°C for 30min and then solution of 33 (0.192 g, 0.40mmol) in
methanol (5 mL) was added. Reactionmixture was stirred at 0°C for 1 h
and then at room temperature overnight. Then solventwas evaporated
under reduced pressure and crude product dissolved in water (5 mL).
Water phase was extracted with ethyl acetate (3 × 20mL), combined
organic phases washed with brine (30mL), dried over Na2SO4, filtered
and the solvent removed under reduced pressure. Yield: 0.130 g
(86.7%); yellow solid; mp 135–137°C; 1H NMR (400MHz, DMSO-d6):
δ 1.08 (t, 3H, J = 7.2 Hz, NHCH2CH3), 3.13–3.20 (m, 2H, NHCH2CH3),
3.60 (s, 2H, CH2), 5.03 (s, 2H, NH2), 6.63 (dd, 1H, J1 = 8.6 Hz,
J2 = 2.2 Hz, Ar-H-5), 6.68 (t, 1H, J = 5.6 Hz, NHCH2CH3), 6.92 (s, 1H,
thiazole-H), 6.94 (d, 1H, J = 2.2 Hz, Ar-H-7), 7.28 (d, 1H, J = 8.6 Hz, Ar-
H-4), 10.28 (s, 1H, NHCO) ppm, signal for NHCO not seen in the
spectrum; HRMS (ESI−) m/z for C15H16N6O2S2 ([M–H]
−): calcd.




A solution of 35 (0.100 g, 0.27 mmol) and triethylamine (0.092 mL,
0.67 mmol) in 1,4-dioxane (10 mL) was cooled to 0°C on an ice bath
under an argon atmosphere. Then methyl 3-chloro-3-oxopropanoate
(0.035 mL, 0.32 mmol) was added dropwise. The reaction mixture
was stirred at room temperature overnight. Then solvent was
evaporated under reduced pressure and the residue dissolved in
ethyl acetate (20 mL). Organic phase was successively washed with
1% citric acid (2 × 10mL), saturated aqueous NaHCO3 solution
(2 × 10mL) and brine (10 mL), dried over Na2SO4, filtered and the
solvent removed under reduced pressure. Crude product purified by
flash column chromatography using dichloromethane/methanol
(20:1) as eluent. Yield: 0.016 g (12.6%); yellow solid; mp 129–
131°C; 1H NMR (400MHz, MeOD-d4): δ 1.23 (t, 3H, J = 7.2 Hz,
NHCH2CH3), 3.31–3.33 (m, 2H, NHCH2CH3; signal partially over-
lapped with solvent residual peak), 3.74 (s, 3H, CH3), 3.77 (s, 2H,
CH2), 3.80 (s, 2H, CH2), 7.00 (s, 1H, thiazole-H), 7.45 (dd, 1H,
J1 = 8.7 Hz, J2 = 2.1 Hz, Ar-H-5), 7.59 (d, 1H, J = 8.7 Hz, Ar-H-4), 7.28
(d, 1H, J = 2.1 Hz, Ar-H-7) ppm, signals for NH groups not seen in the
spectrum; HRMS (ESI+) m/z for C19H21N6O5S2 ([M+H]
+): calcd.
477.1015, found 477.1026; HPLC: method A, tr 10.76min (100% at
254 nm).
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Ethyl 2-((4-(2-((2-(3-ethylureido)benzo[1,2-d]thiazol-6-yl)-
amino)-2-oxoethyl)thiazol-2-yl)amino)-2-oxoacetate (37)
A solution of 35 (0.200 g, 0.53 mmol) and triethylamine (0.185 mL,
1.33 mmol) in 1,4-dioxane (20mL) was cooled to 0°C on an ice bath
under an argon atmosphere. Then ethyl 2-chloro-2-oxoacetate
(0.071 mL, 0.64 mmol) was added dropwise. The reaction mixture
was stirred at room temperature overnight. Then solvent was
evaporated under reduced pressure and crude product purified by
flash column chromatography using dichloromethane/methanol
(30:1) as eluent. Yield: 0.048 g (19.0%); yellow solid; mp 141–
143°C; 1H NMR (400MHz, DMSO-d6): δ 1.09 (t, 3H, J = 7.2 Hz,
NHCH2CH3), 1.31 (t, 3H, J = 7.1 Hz, COOCH2CH3), 3.15–3.22 (m,
2H, NHCH2CH3), 3.77 (s, 2H, CH2), 4.30 (q, 2H, J = 7.1 Hz,
COOCH2CH3), 6.70 (t, 1H, J = 4.9 Hz, NHCH2CH3), 7.16 (s, 1H,
thiazole-H), 7.47 (dd, 1H, J1 = 8.7 Hz, J2 = 2.0 Hz, Ar-H-5), 7.55 (d,
1H, J = 8.7 Hz, Ar-H-4), 7.28 (d, 1H, J = 2.0 Hz, Ar-H-7), 10.25 (s, 1H,
NHCO), 10.63 (s, 1H, NHCO), 12.99 (s, 1H, NHCO) ppm; 13C NMR
(100MHz, DMSO-d6): δ 13.7, 15.1, 34.2, 40.1, 62.5, 111.4, 111.7,
118.1, 119.5, 131.8, 134.3, 145.2, 145.7, 153.6, 158.9, 167.4, 167.5,
175.1, 179.6 ppm; HRMS (ESI+) m/z for C19H21N6O5S2 ([M+H]
+):
calcd. 477.1015, found 477.1009; HPLC: method A, tr 11.25 min
(95.1% at 254 nm).
2-((4-(2-((2-(3-Ethylureido)benzo[1,2-d]thiazol-6-yl)amino)-2-
oxoethyl)thiazol-2-yl)amino)-2-oxoacetic acid (38)
To a solution of 37 (0.025 g, 0.053mmol) in methanol (5 mL), 1M
NaOH (0.11mL, 0.11mmol) was added and the reaction mixture
stirred at room temperature overnight. Then the acidic ion exchange
resin Amberlite® IR120 H was added for neutralization (pH∼ 6). After
stirring of mixture for 10min, the resin was filtered off, washed with
methanol and the solvent removed in vacuo. Yield: 0.017 g (72.3%);
orange solid; mp >300°C; 1HNMR (400MHz, DMSO-d6): δ 1.06 (t, 3H,
J = 7.2 Hz, NHCH2CH3), 3.10–3.17 (m, 2H, NHCH2CH3), 3.68 (s, 2H,
CH2), 6.96 (s, 1H, thiazole-H), 7.19 (br s, 1H, NHCH2CH3), 7.28–7.37
(m, 2H, Ar-H-4, Ar-H-5), 8.03 (s, 1H, Ar-H-7), 10.11 (s, 1H, NHCO)
ppm; signals for NH groups are not seen in the spectrum; 13CNMR
(100MHz, DMSO-d6): δ 15.2, 34.2, 40.1, 109.8, 111.5, 118.0, 119.5,
131.8, 135.4, 145.1, 145.5, 152.8, 156.5, 159.8, 164.6, 167.6,
170.5 ppm; HRMS (ESI+) m/z for C17H15N6O5S2 ([M–H]
−): calcd.
447.0545, found 447.0532; HPLC: method A, tr 9.64min (95.2% at
254 nm).
4.2 | Molecular modeling
4.2.1 | Ligand and protein preparation
Three-dimensional models of designed compounds were built in
ChemBio3D Ultra 13.0.[30] Their geometries were optimized using
MMFF94[31] force field and partial atomic charges were added.
Energy was minimized until the gradient value was smaller than
0.001 kcal/(mol Å). The optimized structure was further refined with
GAMESS interface in ChemBio3D Ultra 13.0 using the semiempirical
PM3 method, QA optimization algorithm and Gasteiger Hückel
charges for all atoms for 100 steps.[30] Molecular docking calculations
were performed using FlexX,[32,33] as available in LeadIT,[34] running on
four octal core AMD Opteron CPU processors, 16 GB RAM, two 750
GB hard drives, running 64-bit Scientific Linux 6.0. Receptor was
prepared in a LeadIT graphical user interface using the Receptor
wizard. Amino acid residues within a radius of 7 Å around the ligand
from the X-ray structure (PDB entry: 4DUH[29]) were defined as the
binding site. Hydrogen atoms were added to the binding site residues
and correct tautomers and protonation states were assigned. Water
molecules, except HOH614, and the ligand were deleted from the
crystal structure.
The FlexX molecular docking program, as available in LeadIT,[34]
was used for ligand docking. A hybrid algorithm (enthalpy and entropy
driven ligand binding) was used to place the “base fragment”. The
maximum number of solutions per iteration and the maximum number
of solutions per fragmentation parameter values were increased to
1000, while other parameters were set at their default values. In order
to validate our docking protocol, crystal structure ligand was docked
into the defined ATP-binding site of E. coli GyrB using the above
described docking parameters. The protocol was able to reproduce the
binding of the crystal structure ligand with an RMSD value of 1.2 Å,
which highlights the docking protocol as suitable for binding mode
studies of the designed DNA gyrase inhibitors that were docked using
the same settings as used for docking protocol validation. Proposed
binding modes and scoring function scores of the top five highest
scored docking poses per ligand were evaluated and the highest
ranked binding pose was used for graphical representation in
PyMOL.[35]
4.3 | Biological activity assays
4.3.1 | In vitro inhibitory activity screening and
determination of IC50 values on E. coli DNA gyrase
The assay for determining IC50 values (Inspiralis) was performed on
black streptavidin-coated 96-well microtiter plates (Thermo Scien-
tific Pierce). The plate was first rehydrated with the wash buffer
supplied (20 mM Tris-HCl (pH 7.6), 137 mM NaCl, 0.01% (w/v) BSA,
0.05% (v/v) Tween 20). Biotinylated oligonucleotide in wash buffer
was immobilized onto the wells. The excess of oligonucleotide was
then washed off and the enzyme assay carried out in the wells
(5 min). The final reaction volume of 30 µL in buffer (35 mM Tris-
HCl (pH 7.5); 24 mM KCl; 4 mM MgCl2; 2 mM DTT; 1.8 mM
spermidine; 1 mM ATP; 6.5% (w/v) glycerol; 0.1 mg/mL albumin)
contained 1.5 U of DNA gyrase from E. coli, 0.75 µg of relaxed
pNO1 plasmid, and 3 µL of inhibitors solution in 10% DMSO and
0.008% Tween® 20. Reactions were incubated for 30 min at
37°C and, after addition of the TF buffer (50 mM NaOAc (pH 5.0),
50 mM NaCl and 50 mM MgCl2), which terminated the enzymatic
reaction, for another 30 min at room temperature to allow triplex
formation (biotin–oligonucleotide–plasmid). The unbound plasmid
was then washed off using TF buffer, and a solution of SybrGOLD
stain in T10 buffer (10 mM Tris-HCl (pH 8.0) and 1 mM EDTA) was
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added. After mixing, the fluorescence (excitation, 485 nm; emis-
sion, 535 nm) was read using a BioTek Synergy H4 microplate
reader. Preliminary screening was performed at inhibitor concen-
trations of 100 and 10 μM. For the most potent compounds, IC50
was determined with seven concentrations of the inhibitors. IC50
values were calculated using GraphPad Prism software and
represent the concentration of inhibitor where the residual activity
of the enzyme is 50% in three independent measurements; the final
result is given as their average value. Novobiocin (IC50 = 0.17 μM)
was used as a positive control.
4.3.2 | Determination of antibacterial activity
Clinical control strains of E. faecalis (Gram positive, ATCC 29212), S.
aureus (Gram positive, ATCC 25923), E. coli (Gram negative, ATCC
25922), and P. aeruginosa (Gram negative, ATCC 27853), were
obtained from Microbiologics Inc. (St. Cloud, Minnesota, USA).
Single-gene knock-out mutant strains of E. coli, JW5503 (tolC knock-
out)[36] and JD17464 (lpxC knock-out), were obtained from the
NBRP-E.coli collection at National Institute of Genetics (NIG, Japan).
Antimicrobial testing was carried out by using the broth micro-
dilution method in 96-well plate format according to the CLSI
guidelines.[37] Briefly, bacterial suspensions yielding final inoculum of
5 × 105 CFU/mL were prepared into cation-adjusted Mueller Hinton
broth (Becton Dickinson, Franklin Lakes, NJ, USA) and mixed on the
plate with test compound solution diluted into assay media. After
incubating the plate for 24 h at 37°C, absorbance values were
measured at 620 nm and used for evaluating the antimicrobial
effects of test compounds by comparing to untreated controls and
expressed as percentage inhibition of growth. Ciprofloxacin was
used as a positive control on every assay plate (minimum inhibitory
concentration [MIC] against E. faecalis, S. aureus, E. coli, and P.
aeruginosa, was 3.0, 1.5, 0.05, and 3.0 μM, respectively). All
compounds were initially assayed at final concentration of 50 μM
(n = 3). For compound 33 that displayed ≥80% inhibition at 50 μM,
MIC (lowest concentration that inhibited the growth by ≥90%) was
determined by carrying out dose-response experiments at eight
different concentrations.
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